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ABSTRACT 
The predominant form of human butyrylcholinesterse (BChE) in blood is a tetramer 
complex of four identical subunits. While, the recombinant BChE in Chinese hamster 
ovary (CHO) cells consists mainly dimers and a small amount of monomers. In current 
biopharmaceutical industry, mammalian cell culture platforms, especially CHO cells, are 
predominantly used for the production of therapeutic glycoproteins. 
We have developed an efficient BChE expression system in CHO cells by exploring 
various combinations of different promoters, codon optimization effect and 6xhistidine-tag 
effect. Then we transfected three proline-rich sequences of different proline lengths (P8, 
P14 and P24) respectively into recombinant human BChE (rhBChE) stably expressing cell 
line and determined individual’s isomer distribution by native electrophoresis and 
enzymatic activity by Ellman assay. P24 was able to organize more than 60% of rhBChE-
his into tetramers.  We tested BChE purification efficiency by using Ni-NTA purification 
system. To further enhance the tetramer content in rhBChE expressing cell line, we used 
fluorescence-activated cell sorting method, which has remarkably increased P24 sequence 
expression level. In this thesis, we have performed a bioprocess to produce recombinant 
huBChE tetramers in Chinese Hamster Ovary (CHO) Cells. We have created two cell lines 
from CHO that will be further studied and optimized for the production of rhBChE: CHO-
rhBChE, CHO-rhBChE-P24. 
Advisor: Dr. Michael Betenbaugh  
Reader: Dr. Kevin Yarema
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CHAPTER 1: INTRODUCTION 
1.1 HUMAN BUTYRYLCHOLINESTERASE STRUCTURE AND FUNCTION   
Butyrylcholinesterase (BChE) is a serine hydrolase which has gained a lot 
attention because it hydrolyzes cocaine, heroin, aspirin, bambuterol and succinylcholine, 
and it scavenges organophosphorus pesticides and chemical warfare agents, which is also 
called organophosphorus bioscavenger[1-6]. 
Amino acid sequencing of the mature BChE enzyme isolated from human plasma 
revealed that each subunit comprise 574 residues with a molecular mass of 85 000 Da 
and nine N-linked carbohydrates [7]. Reports pointed out that pharmacokinetic properties 
of the recombinant BCHE are affected by both glycosylation and size of the recombinant 
protein [8, 9]. Oligosaccharide profiles of recombinant human BCHEs showed significant 
difference compared with native plasma enzyme [8, 10]. But the most important 
characteristic for the bioscavenger, i.e., half-life [11], is mainly dependent on the size of 
the protein [12]. 
The predominant form of human BChE in blood is a tetrameric complex of four 
identical subunits, as shown in Figure 1. To date, BChE comes as a single variant: 
BChET, which possesses a C-terminal t-peptide similar to that of AChET 
(acetylcholinesterase) [13, 14]. The t-peptide of BChET is called the tryptophan 
amphiphilic tetramerization (WAT) domain, containing seven strictly conserved aromatic 
residues (Trp 543, Phe 547, Trp 550, Tyr 553, Trp 557, Phe 561, and Tyr 564), including 
three evenly spaced tryptophans and is organized as a α-helix [15]. WAT domain is 
located within the last 40 C-terminal residues [16].  These seven residues are responsible 
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for stabilizing BChE and mediating the interactions that increase tetrameric assembly 
when BChE subunits are interacting with its tetrameric partners. 
 
 
Figure 1. Structural model of the human BChE-tetramers showing with the polyproline peptide 
located in the core of the tetramerization domain. (A) Human BChE viewed from the top. (B) Human 
BChE tetramer viewed from the side [17]. 
The half-life of BChE (wild type or mutant) in circulation is dependent on the 
quaternary form of the protein. The residence time of the monomer is only on the order of 
minutes in the circulation of mice, whereas native human BChE has a half-life of ∼46 h 
in mice [8, 18, 19] or ∼12 days in human plasma [20]. It has been shown that the 
predominant forms of recombinant BChE secreted from Chinese hamster ovary (CHO) 
cells were monomers and dimers, whereas native BChE consists more than 95% of 
tetramers that lead to the longer half-life of native BChE in plasma [14, 17, 19].  
According to the studies about BCHE, the tetrameric forms of BChE are inserted 
in the basal lamina of neuromuscular junctions or anchored in cell membranes through 
the interaction of four C-terminal peptides with proline-rich attachment domains 
(PRADs) of cholinesterase-associated collagen Q or of the transmembrane protein 
PRiMA (proline-rich membrane anchor) [21, 22], as depicted in Figure 2. ColQ and 
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PRiMA differ in the length of their proline-rich motifs (10 and 15 redidues, repectively) 
(Fig2). Duysen et al. [19] reported that coexpression in CHO cells of BChE and PRAD of 
ColQ yielded 70% tetrameric BChE and 30% monomer and almost no dimer. While 
Ilyushin et al. [12] reported coexpression of rhBChE and PRAD of ColQ in CHO cells 
showed BChE 50% dimers and 50% tetramers primarily expressed and no monomer 
detectable in the culture medium. Furthermore, He li et al  [21]extracted a series of 
proline-rich peptides from denatured human and horse plasma BChE, which have the 
same proline-rich core sequence PSPPLPPPPPPPPPPPPPPPPPPPPLP (mass 2663 Da) 
but varied in length at their N- and C-termini. Collectively, hundreds of reports have 
demonstrated that the proline-rich peptides organize the 4 subunits of BChE into a 340 
kDa tetramer by interacting with the C-terminal tetramerization domain of each subunit. 
 
PRAD of ColQ (P8): CCLLTPPPPPLFPPPFF 
PRAD of PRiMA(P14): CQCRPPPPLPPPPPPPPPPRLL 
The core proline-rich sequence extracted from human plasma (P24):                            
PSPPLPPPPPPPPPPPPPPPPPPPPLP 
 
Figure 2 Three proline-rich sequences, written with the N-terminus on the left and the C-terminus on 
the right. PRAD of ColQ is abbreviated as P8, which has 8 proline residues; PRAD of PRiMA is 
abbreviated as P14, which has 14 proline residues; the core proline-rich sequence extracted from human 
plasma is abbreviated as P24, which has 24 proline residues. 
 
 
Moreover, Marilynn A. Larson et al. [23] reported that 90-98% of purified rBChE 
(65 uM) could be assembled into tetramers when incubated with synthetic 17-mer or 50-
mer polyproline peptides (100uM) for 1.5h at 25℃. Thus, the process of assembling 
active BChE into tetramers could occur in vitro in the presence of appropriate BChE and 
polyproline peptide concentrations.  
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 However, the published results of coexpression of rBChE and PRAD of ColQ is 
self-controversial and it has been reported that rBChE tetramerization was inefficient 
with smaller 8-mer polyproline peptide [23]. Additionally, no documents reported the 
performance of introduction of PRAD of PRiMA and the proline-rich core sequence 
extracted from human BChE into CHO BChE expressing cell line in vivo. Plus, in vivo 
assembly could avoid the high concentrations of rBChE and polyproline peptide required 
for in vitro assembly. 
Therefore, developing a CHO expression system to force in vivo tetramerization 
of recombinant BChE would be beneficial. In this study, I first developed an efficient 
BChE expression system in CHO cells, and then introduced three Polyproline-rich 
sequences (P8: PRAD of ColQ, P14: PRAD of PRiMA and P24: proline-rich core 
sequence extracted from human BChE) respectively into the CHO-K1 cells expressing 
recombinant human BChE.   
1.2 NI-NTA PURIFICATION OF RHBCHE 
 A common used approach to purify rhBChE is to use BChE affinity on 
procainamide, which is a small molecule that binds strongly on the enzyme’s substrate 
binding site [24]. However, some BChE variants, like G117H/E197Q BChE, have little 
affinity for procainamide, and thus are not efficient purification using a procainamide 
column [25, 26]. Therefore, there is a need for a robust BChE purification method 
regardless of the rhBChE’s three-dimensional structure. Affinity tags are a logical choice 
[25].   
A polyhistidine-tag is an amino acid motif consisting of at least six histidine (His) 
residues, often added at the N- or C-terminus of the target protein. Histidine exhibits a 
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very strong interaction with metal ions like Co2+, Ni2+, Cu2+, Zn2+. For instance, his-
tagged protein can bind to the Ni-NTA groups on the matrix with an affinity for greater 
than that of anti-body antigen or enzyme-substrate interactions. And a widely employed 
protein purification method utilizes immobilized metal-affinity chromatography (IMAC) 
to purify recombinant protiens containing a polyhistidine-tag [27].  
1.3FLUORESCENCE ACTIVATED CELL SORTING 
Fluorescence-activated cell sorting (FACS) is a specialized application of flow 
cytometry. It provides a method for sorting a heterogeneous mixture of cells into two or 
more containers, one cell at a time, based upon the specific fluorescent characteristics of 
each cell. It is a useful scientific instrument as it provides fast, objective and quantitative 
recording of fluorescent signals from individual cells as well as physical separation of 
cells of particular interest [28].  
The use of internal ribosome entry sites (IRESs) in dicistronic expression vectors 
enables the expression of two genes controlled by one promoter in target cells [29]. 
Usually, IRES is linked between a target gene and an autofluorescent reporter gene such 
as green fluorescent protein (GFP) to create a dicistronic vector. Thus, the construct of 
P24 linked with IRES-GFP would be valuable. And the use of FACS provides a higher 






CHAPTER 2: MATERIALS AND METHODS 
2.1 CONSTRUCTION OF EXPRESSION VECTORS 
 Gene constructs, pcDNA3.1/v5-his-TOPO-huBChE, was kindly obtained from Dr. 
Ashima Saxema at the Walter Reed Army Institute of Research in Silver Spring, MD. The 
DNA fragment encoding the open reading frame of huBChE (human BChE) was amplified 
by PCR using a 5’ primer containing an EcoRV site, 5’-
GCCGATATCGCCACCATGGATAGCAAAGTCACAATCA-3’ and a 3’ primer 
containing a PacI site, 5’-
GCCTTAATTAACTATTATCAAGACCCACACAACTTTCTTTC-3’, and the 
pcDNA3.1/v5-his-TOPO-huBCHE construct as a template. The sequences of human 
BChE and P8, P14 and P24 were codon optimized to fit expression in CHO cells from 
Biomatik. BChE-his was constructed by fusing the C-terminus of BChE with a 6x his tag. 
A set of BChE combinations including BChE, BChE-his, Codon-optimized BChE(O-
BChE) and Codon-optimized BChE-his (O-BChE-his), were inserted into pcDNA3.1 
vector though HindIII and BamHI separately. The same set of BChE combinations (BChE, 
BChE-his, O-BChE, O-BChE-his) were inserted into pEF6/V5-his TOPO TA vector 
(Addgene) through BamHI and NotI and pCHO1.0 vector (Life Technologies) through 
EcoRV and PacI respectively. These vector constructs are shown in Figure 3. 
Besides, pcDNA-PRAD plasmids were constructed by inserting the corresponding 
proline-rich sequences (P8, P14 and P24) fused with a flag tag into pcDNA3/Hgy(+) 
through HindIII and BamHI sites individually.  
For pcDNA3.1 P24-IRES-GFP construct, codon optimized P24 sequence was 
introduced into pcDNA3.1 vector through NhelI and HindIII sites followed by IRES 
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sequence inserted between HindIII and NotI sites. Then, GFP sequence was inserted 
between NotI and Xhol sites right after IRES sequence.  
 
Figure 3 Expression vectors used in developing an efficient rhBChE-his system. 
2.2 CELL CULTURE AND TRANSFECTION 
 Adherent CHO-K1 cell lines (Sigma-Aldrich, St. Louis, MO) were maintained in 
adherent growth flasks (Sarstedt, Numbrect, Germany) in Ham’s F-12K (Life 
Technologies, Carlsbad, CA) Medium supplemented with 10% fetal bovine serum, FBS 
(Thermo Scientific, Logan, UT), 20 mM L-glutamine (Corning Cellgro Manassas, VA), 
and 1% non-essential amino acids (Invitrogen, Carlsbad, CA). Cells were grown at 37oC 
with 5% CO2 in a Series 8000 – Direct Heat and Water Jacket CO2 incubator (Thermo 
Scientific, Waltham, MA). When greater than 90% confluency was reached, cells were 
passaged using 0.25% Trypsin-EDTA (Life Technologies, Carlsbad, CA) to release the 
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adherent cells from the flask. Depending on the confluency of the cells, cells were passaged 
at a ratio of 1:10 to 1:20 for general maintenance and continued growth. For transfection, 
cells were seeded onto a 6-well plate at appropriate densities in 2 ml of media each well 24 
hours prior to transfection. When the cells were at around 90% confluency, DNA constructs 
were transfected into cells using lipofectamine 3000 kit (Invitrogen) and Optimum media 
(Invitrogen), according to the manufacturer’s instructions. At each stage, transfected stable 
pools were obtained based on antibiotic selection using blasticidin (Invitrogen) for BCHE, 
Zeocin (Invitrogen) for P14 or P24. Stable pool media was replaced with new media and 
fresh antibiotics every 3-4 days until cell viability was below 10% in wild-type CHO-K1 
cells. Stable pools were then passaged 4-5 times to ensure recovery of cell growth. Stable 
single clones were established by seeding 0.8 cell/well in 96-well plates (Corning, 
Tewksbury, MA) for limited dilution.  
2.3 IMMUNOBLOTING 
Conditioned cell media was harvested from the adherent rhBChE cells, and the 
supernatant was removed for analysis of secreted protein. For SDS-PAGE, the media 
samples were stained with SDS loading dye and subsequently denatured by heating at 95oC 
for 5 minutes. SDS loading dye is composed of 250 mM Tris (pH 6.8), 1% 2-
mercaptaethanol (Sigma-Aldrich, St. Louis, MO), 50% glycerol (Sigma-Aldrich, St. Louis, 
MO), 5% SDS, 0.29% Bromophenol Blue (Sigma-Aldrich, St. Louis, MO), 20 mM 
Dithiothreitol DDT (Sigma-Aldrich, St. Louis, MO) and stored at -20 ℃ freezer. 
Samples were loaded onto 10% polyacrylamide gels, for detection of rhBChE under 
combinantions of various promoters, his-tag and gene codon optimization. The SDS gels 
are composed of various amounts of water, 30% Bis-Acrylamide (BIO-RAD, Hercules, 
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CA), Tris-HCL (Promega, Fitchburg, WI), 10% SDS, 10% APS, TEMED (Invitrogen, 
Carlsbad, CA). Proteins were separated using gel electrophoresis run at 70V constant 
voltage through the stacking gel, and then 110V constant voltage through the resolving gel 
for 90 minutes at room temperature. Proteins were transferred from the gel to nitrocellulose 
membranes (BIO-RAD, Hercules, CA) by blotting for 75 minutes at constant 100V. 
Transferred membranes were blocked in 5% milk solution in Phosphate Buffered Saline 
(Corning Cellgro, Manassas, VA) with 0.1% Tween-20 (PBST) for 1 h.  Membranes were 
washed three with PBST for 10 minutes each time. Membranes were incubated in a 1% 
milk in PBST solution containing 1:1000 dilution of anti-huBChE rabbit serum (kindly 
provided by Dr. Ashima Saxena) as primary antibody overnight at 4oC for huBChE 
detection. Membranes were then washed 4 times with PBST. Membranes were incubated 
in 1% milk in PBST solutions containing 1:2000 dilution of a horseradish peroxidase-
linked anti-rabbit IgG antibody (Amersham, Louisville, CO) as a secondary antibody for 2 
hours at room temperature for huBChE detection. After washing the membrane 3 more 
times, chemiluminescent detection of the bound antibody was achieved using Immun-Star 
WesternC Chemiluminescent Kit (BIO-RAD, Hercules, CA) on the Molecular Imager® 
ChemiDoc™ XRS (BIO-RAD, Hercules, CA) with Quantity One Software (BIO-RAD, 
Hercules, CA). 
2.4 NATIVE GEL ELECTROPHORESIS 
 For native gel electrophoresis, media samples were neither denatured nor reduced. 
Media samples were stained with a loading dye composed of same chemicals as SDS 
loading dye described above except for SDS, 2-mercaptaethanol, or 20 mM Dithiothreitol. 
Buffer conditions for running native gel electrophoresis are run without SDS. HuBChE 
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activity was detected on the gel by a method developed by Karnowsky and Roots [30]. 
Briefly, gels were incubated in 100 mM phosphate buffer, pH 7.0, containing 5 mg of 
thiocholine ester, 0.5 ml of 100 mM sodium citrate, 1.0 ml of 30 mM copper sulphate, and 
1.0 ml of 5 mM potassium ferricyanide in a total volume of 10 ml for 20 mins. The gel is 
then treated with ammonium sulphide solution for 5 mins to form brown bands on the gel.  
2.5 ELLMAN ACTIVITY ASSAY 
 Purified Conditioned cell media was harvested from adherent CHO-K1 cells. 
Reagents for Ellman Assay were kindly obtained from Dr. Saxena Ashima. 10 µl of media 
was added in duplicate to wells of a 96-well microtiter plate (Corning, Manassas, VA), 
with each well contained 240 µl of 50 mM Phophate Buffer, pH 8.0 and 1.3mM DTNB 
(PB-DTNB) [31]. Mixture was incubated at room temperature for 20 minutes, and then 50 
µl of 6 mM BTC in PB was added. The rate of BTC hydrolysis was read at 412 nm over 
10 minutes using a SPECTRAmax PLUS plate reader (Molecular Devices Corp., 
Sunnyvale, CA) and the SoftMax Pro software (Molecular Devices Corp., Sunnyvale, CA).  
Wells that contained only PB-DTNB without cells were measured as blanks.  
2.6 PURIFICATION OF BUTYRYLCHOLINESTERASE 
The rhBChE stabe cell line was seeded at 1x106 million cells per 100mm tissue 
dish. Let the cells growing for two days until the confluency was above 95%, then change 
the growth media to Opti-mum reduced serum media (Thermo Fisher Scientific). The cells 
were incubated for additional two days and then harvested the Opti-mum media and 
centrifuged to remove cell pellet and collected the supernatant.  
For Ni-NTA purification, 200ul 50% Ni-NTA agarose slurry was added into 14ml 
supernatant and mixed gently by shaking 100 rpm on a rotary shaker for 1 h at room  
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temperature, then loaded the supernatant-Ni-NTA mixture into a column and collected the 
flow-through. Wash three times with appropriate volume with washing buffer (20 mM 
imidazole in PBS solution) and collect wash fractions, and the bound BChE was eluted 
with  1.5 ml elution buffer (250 mM imidazole in PBS solution). After elution, the eluate 
was immediately dialyzed with PBS buffer three times using 10 Kd ultrafiltration column 
(AmiconUltra, Millipore). In the last step of dialysis, collect the sample until the total 
volume is 300ul. Then the purified rhBChE was evaluated using Ellman assay to determine 
the active form of rhBChE in different fractions and native electrophoresis followed by 
K&R staining [30] to determine the isomers of rhBChE after his-tag purification. 
2.7 FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
After transfecting pcDNA3.1 P24-IRES-GFP into rhBChE stably expressing cell 
line, stable pools were obtained based on antibiotic selections including blasticidin 
(Invitrogen) for BCHE, Zeocin (Invitrogen) for P24. And stable pools were passaged 7-10 
times to ensure appropriate expression of GFP. Then cells in the stable pool were seeded 
at 1x106 cells per dish for three dishes. When the confluency was above 90%, cells were 
washed with PBS (Quality Biological), detached and counted using trypan blue solution 
0.4% (w/v) (Invitrogen) to check cell viability. After above 90% confluency, cells were 
pelleted at 500 g for 15 mins, PBS washed twice and resuspended in 1.5ml PBS in 12 x 75 
mm Tube with Cell Strainer Cap (BD Falcon). Cells were carried to JHU medical school 
to do flow cytometry.  After cells with strong GFP expression were sorted, sorted cells 
were moved to 50 ml tube with culture media up to 40 ml, centrifuge 2100g for 5 mins to 
remove sorting buffer and culture media and then resuspended cells in a dish with antibiotic 
selection. Three days later, the sorted cells have more than 50% recovery, which mean a 
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CHAPTER 3:  RESULTS  
3.1 THE DEVELOPMENT OF AN EFFICIENT RHBCHE EXPRESSION SYSTEM 
 The first aim of this project is to develop a high-level recombinant human 
butyrylcholinesterase (rhBChE) expression system. Two human BCHE genes are used, one 
in which native codons found in human BCHE cDNA and the other with codon 
optimizations prevalent in CHO genes. Relative performances of these two BCHE genes 
were evaluated with combinantions of different promoters and his-tag.  
































Figure 4. Assessment of BCHE expression levels under various promoters, gene 
codon optimization and his-tag factors. (A) Ellman Assay detection of huBChE 
activity; (B) Western Blot detection of HuBChE 
  Thus, to select an efficient expression system, 12 expression vectors ( 
pcDNA3.1/CMV/BCHE, pcDNA3.1/CMV/BCHE-HIS, pcDNA3.1/CMV/O-BCHE, 
pcDNA3.1/CMV/O-BCHE-HIS, pEF6/EF/BCHE, pEF6/EF/BCHE-HIS, pEF6/EF/O-
BCHE, pEF6/EF/O-BCHE-HIS, pCHO1.0/CMV+EF-1 Hybrid/BCHE, 
pCHO1.0/CMV+EF-1 Hybrid/BCHE-HIS, pCHO1.0/CMV+EF-1 Hybrid/O-BCHE and 
pCHO1.0/CMV+EF-1 Hybrid/O-BCHE-HIS) were constructed (Fig. 3) and transiently 
transfected into CHO-K1 cells via lipofection. Culture media of 12 transfectomas were 
collected 48 h following the transfection. Conditioned medium of CHO-K1 cell line grown 
under the same conditions as transfectomas were used as a control. Equal volume of post-
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transfection conditioned cell media was loaded into each lane of a 10% polyacrylamide gel 
to run SDS-PAGE. Following SDS-PAGE, we analyzed the proteins using western blot 
analysis and the Ellman Activity Assay as shown in Figure 4. A band for recombinant 
huBChE is observed at the same molecular weight (~80-90 kDa). In addition, there is no 
band at that molecular weight observed in untransfected wild-type CHO cells, indicating a 
successful transient transfection of huBChE into CHO. The Western blot analysis was 
consistent with the Ellman assay results. 
According to the Beer-Lambert law, A=εlc, where A is the absorbance measured in 
optical density (OD/min), ε is the molar adsorptivity, for TNB-, the colorimetric product 
of DNTB the value is 13260M-1cm-1 [George L Ellman, 1960], l is the pathlengh and the 
path lengths of the 96-well plate wells containing a total volume of 300 µl (reaction 
volume) was ~0.32 cm, c is the concentration, mathematical conversion will yield moles 
of TNB per min and the reaction ratio of BTC:BChE:DNTB is 1:1:1. The activity of 
purified huBChE was calculated to be ~2100 Units (U)/ml, with one unit of enzyme activity 
defined as the amount of enzyme that hydrolyzes one micromole of TNB in 1 minute. The 
results shown in Fig.2A demonstrate that the rhBChE activity of the vector 
pEF6/EF/BCHE-HIS and pEF6/EF/O-BCHE-HIs were comparable and were equal to 
approximately 0.49 U/ml and 0.46 U/ml, which is an approximately 6-fold increase 
compared to the level of human BCHE cDNA with CMV promoter (0.08 U/ml).  
Interestingly, with CMV promoter, codon optimization can remarkably enhance the 
expressions of BCHE and BCHE-HIS, which don’t have an obvious effect on other 
promoters.  Using codon optimization, the expression levels of BCHE and BCHE-HIS 
under CMV promoter were 0.28 U/ml and 0.38 U/ml, which showed 3.5-fold and 4.8-fold 
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increase compared to the levels of BCHE cDNA counterparts respectively. And there was 
no huBChE activity detected in the WT CHO conditioned cell medium. 
Therefore, the vector pEF6/EF/O-BCHE-HIS containing the codon-optimized 
BCHE gene under the control of the EF promoter (elongation factor 1a) and a C-terminal 
his-tag was selected and applied in the following experiments as an efficient BCHE 
expression construct. 
 
3.2 ENHANCEMENT OF RECOMBINANT HUMAN BCHE  TETRAMERIZATION IN 
VIVO   
Figure 5 Determine the length of proline-rich sequence required for efficiently assembly of rhBChE 
























Table 1 Quantification of BChE isomer distribution by determining band intensity using ImageJ 
analysis.  
 
 P8 P14 P24 NC 
Tetramer/% 35.14296 48.36261 59.51934 9.518602 
Dimer/% 57.63332 48.51981 35.85448 71.58532 
Monomer/% 7.223716 3.117586 4.626178 18.89607 
     
 
 Overexpression of P8, P14 and P24 polyproline sequences in rBChE stably 
expressing CHO cell line. Two days post-transfection, 2 ml supernatant of each sample 
was concentrated, dialyzed and then fractionated in a non-denaturing gel. To visualize the 
migration of rhBChE, the native gels were stained for BChE activity. Lane1,  rhBChE from 
rhBCHE producing CHO cell; Lane2, purified human plasma BChE; Lane3-5, transient 
expression P8, P14 and P24 sequences on rBChE-prducing CHO cells; Lane6, transient 
expression of empty PcDNA3.1 vector on rBhCE producing CHO cells.  
After tranfection, pEF6/EF/O-BChE-his stable pools were selected under pressure of 10 
µg/ml Blasticidin antibiotic, resulting in production of monoclone. Analysis of secreted 
rhBChE produced by pEF6/EF/O-BChE-his monoclones showed that rhBChE was 
expressed primarily as dimer (Figure 2, lane1). Thus, the next aim is to enhance rhBChE 
tetramerization in CHO expression system.  
Proline-rich sequences of various poplyproline lengths (P8, P14 and P24) were 
separately constructed into pcDNA3.1 vector and individually introduced into rhBChE 
stably expressing cell line. And pcDNA3.1 empty vector was also introduced into the 
rhBChE stably expressing cell line as a control. As shown in Figure 2, a very remarkable 
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difference is the increasing band intensity of rhBChE tetramer from P8 to P24 gradually. 
Furthermore, in order to quantify the content of rhBChE isomers after coexpression of 
proline-rich sequences, ImageJ analyzer was implemented to quantify the varying band 
intensity on Fig.2. In Table 1, rhBChE produced in CHO cells were predominantly dimers 
and a small portion of monomers, which is consistent with some published documents [32].  
Approximately 60% of rhBChE was in the tetrameric form after introducing P24 sequence 
into rhBChE cell line and 48% tetramer and 48% dimer existing after introducing P14 into 
rhBChE cell line.  
3.3 PURIIFICATION OF RECOMBINANT HUMAN BCHE PRODUCED IN CHO CELLS
 
Figure 6 Native Gel Electrophoresis of rhuBChE 
Table 2 Ellman Assay result of fractions from Ni-NTA purification 
 Load  Flow-through Washing  Eluate 
U/ml 10.49915  1.454327 0.11595 98.9112 
 















Given the Ellman assay results of fractions on the rhBChE purification, the active 
form of rhBChE was highly enriched in the eluate (98.91 U/ml in 300ul PBS solution) 
compared to that in the loading supernatant (10.5 U/ml in 14ml supernatant). And there 
was some rhBChE existing in the flow-through and almost no rhBChE in the washing 
solution.  The recovery of protein purification was above 20%, which is normal for Ni-
NTA purification [33].  
Moreover, in order to confirm that rhBChE self-assembly is unaffected by Ni-NTA 
purification process, the purified rhBChE was ran on native electrophoresis and stained by 
K&R method to distinguish different isomers of purified rhBChE sample. As shown in Fig 
3, the isomer distribution of purified rhBChE-his is similar to that of rhBChE supernatant 
in Fig 2. Thus, Ni-NTA purification with its affinity to his-tagged protein can be used as 
an effective purification system for purifying rhBChE protein.  
3.4 FLUORENCENCE-ACTIVATED CELL SORTING (FACS)  
 








DeltaOD/min 1.0783 0.63705 0.6861 0.00705 






Figure 7 Native electrophoresis of cell sorting effect on rhBChE-P24 stable pool. A: equal loading 
volume condition B: Equal total activity condition 
                              Human plasma             sorted                   unsorted             BCHE           CHOK1 
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Next, to further promote rhBChE self-assembly into tetramer, pcDNA3.1 P24-
IRES-GFP was constructed and transiently transfected into rhBChE stably expressing cell 
line. Stable pools were obtained based on antibiotic selections including blasticidin 
(Invitrogen) for BCHE, Zeocin (Invitrogen) for P24. And stable pools were passaged 7-10 
times to ensure appropriate expression of GFP. Then stable pools were sorted using flow 
cytometry and sorted cells with more than 50% recovery were maintained as rhuBChE-
P24 stably expressing cell line.  
rhBChE-P24 sorted cell line, rhBChE-P24 unsorted cell line, and rhBChE cell line 
were seeded at 1x106 cells per dish with 10 ml nutrient media. CHOK1 wild-type cells 
were also seeded at the same density as a negative control. After the confluency of cells 
was > 90%, nutrient media was removed and 10 ml Optimum media was added in these 
four dishes individually. After two days incubation, supernatants (8ml each sample) were 
collected and centrifuged at 2000 rpm at 4 ℃ until the volume of each sample was 1 ml, 
then PBS washed three times and the last volume of each sample was 100ul.  Meanwhile, 
Ellman assay was conducted to determine the activity of rhBChE in each supernatant.  
After cell sorting, the activity of rhBChE has obviously improved (7.6 U/min) 
compared to unsorted counterpart (4.5 U/ml). And the activity of unsorted BChE+P24 
stable pool (4.5 U/ml), which only performed antibiotic selection, is similar to the activity 
rhBChE cell line (4.8 U/ml).  
Then native electrophoresis was performed based on the same loading volume 
condition and the same total activity condition respectively. On the equal loading volume 
basis, in Fig 4 A, sorted and unsorted BChE+P24, BChE and CHOK1 concentrated media 
were loaded 15 ul individually, and purified BChE from human plasma was loaded 1.5 ul 
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as positive control. From the result of Fig 4A, sorted BChE-P24 stable pool (Lane 2) has 
significantly increased the content of BChE tetramer and obviously decreased the contents 
of dimer and monomer compared to that of unsorted BChE-P24 stable pool (Lane 3). And 
the introduction of P24 into rhBChE cell line (Lane 3) indeed promoted rhBChE self-
assembly into tetramer (Lane 4).  Moreover, on the same total activity basis, rhBChE cell 
line (4.85 U/min, 15 ul loading volume) was chose as a reference. Thus the loading volume 
of sorted and unsorted BChE-P24 were 9.5 ul and 16.2 ul respectively. And the loading 
volume of purified human plasma BChE and CHOK1 were kept the same as these in the 
equal-volume condition above.  At the equal total activity condition, the distribution of 





CHAPTER 4: DISCUSSION 
 Tetramerization of rhBChE not only can enhances enzyme stability and half-life in 
vivo, but also provides four subunits with each containing an active site that can effectively 
engage with and inactivate an organophosphorus nerve agent or pesticide [23]. Since 
endogenously expressed human BChE forms a tetrameric complex with proline-rich 
peptides and it’s not immunogenic [21, 23], we predict that the rhBChE tetramer containing 
P8, P14 or P24 would behave similarly.  
We first studies several factors that may influence the expression of rhBChE in 
CHO cells, like different promoters, codon optimization effect and his-tag effect. The 
attempt to use 6Xhistidine tag at the C termini of rhBChE would provide a convenient, 
economic and robust purification method in BChE purification compared to the commonly 
used but costly procainamide-affinity purification.  The data of Fig 1 A and B demonstrated 
that his-tag didn’t affect the activity or the expression level of rhBChE and the different 
performance of BChE expression could be attributed to multiple factors such as 
transcriptional and translational efficiency.  
The results of Ni-NTA purification (Figure 4, Table 3) suggested that Ni-NTA 
purification didn’t change the distribution of rhBChE in CHO cells. Collectively, Ni-NTA 
purification with its affinity to his-tagged protein can be used as an effective purification 
system for purifying rhBChE protein.  
Furthermore, from the result in Fig 2, in the absence of proline-rich sequences 
coexpression, secreted rhBChE in the culture medium consisted predominantly of the 
dimeric form (Figure 2, lane 1), and a small amounts of monomeric and tetrameric rhBCHE 
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were also apparent in the culture medium. These data suggested that the CHO cells do 
produce a small amount of BChE tetramer, and little is known about whether the existence 
of rhBChE tetrameric complex is due to the synthesis of a very low abundance of proline-
rich peptides in CHO cells or the self-assembly on rhBChE itself.  
In addition, comparing that of the untreated control sample (Figure 2, lane 1), the 
use of P8, P14 and P24 proline-rich sequences increased the abundance of rhBChE 
tetramers in vivo gradually (Figure 2, lanes 3-5). Whereas P8 was somehow inefficient to 
provide this function. Proline-rich sequences containing at least 14 proline residues can 
serve as effective tetramer organizing sequence in vivo.  
One thing that hamper the formation of rhBChE tetramer was insufficient 
concentration of P24 secreted in rhBChe-P24 coexpressed cells. Firstly, we tried 
transfected pcDNA3.1 P24 vector into rhBChE cell line and through 10 times passage with 
appropriate antibiotic selection and limited dilution, we couldn’t obtain a monoclone with 
high BChE tetramer content. Our hypothesis is that the inefficient tetramer expression of 
monoclones is attributed to the low expression of P24 and thus antibiotic selection alone is 
unable to provide a robust rhBChE-P24 expression system. Therefore, we then constructed 
pcDNA3.1 P24-IRES-GFP vector and try to use fluorescence activated cell sorting method 
to select high P24 expression cells based on their green fluorescent level.  
As shown in Table 3, sorted BChE-P24 stable pool had enhanced BChE activity (7.6 
U/min), while unsorted BChE-P24, which were only through antibiotic selections, and 
rhBChE stable cell line had similar BChE activity, 4.5 U/min and 4.85 U/min respectively. 
The activity of purified huBChE was calculated to be ~2100 Units (U)/ml, which is 
consisted of more than 95% tetramer.  In Figure 5 A,  at the same loading volume condition, 
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the tetramer content of sorted stable pool was about three-fold higher than that of unsorted 
stable pool, which means higher P24 concentration assembled more monomers and dimers 
into tetramers in sorted stable pool. Meanwhile, ompared to BChE cell line, unsorted 
BChE-P24 stable pool indeed enhanced tetramer assembly to some extent by using 
antibiotic selection alone, but the secreted P24 content was still insufficient to effectively 
promote BChE tetrameric formation.  Besides, in Figure 5 B, loading at the same total 
activity, the results again proved that increased concentration of P24 in sorted stable pool 
significantly promoted tetrameric formation and tetrameric enhancement provided higher 




CHAPTER 5: CONCLUSION 
 Recombinant therapeutic proteins have changed the face of modern medicine in the 
past decade, and they continue to provide innovative and effective therapies for numerous 
previously refractory illness [34] . Among mammalian systems, the Chinese hamster ovary 
(CHO) cells are the pre-eminent choice, accounting for nearly 70% of all recombinant 
protein therapeutics currently produced [34-36]. The CHO cell at its height of technological 
prominence is related to its ease of transfection and adaptation to growth in various culture 
conditions, plasticity in the context of genetic alterations, and the capacity to perform post-
translational modifications compatible with humans [34, 37-40]. In this context, 
genetically engineering recombinant human BChE produced in CHO cells has become a 
good candidate as bioscavenger because it hydrolyzes or scavenges a wide range of toxic 
compounds including cocaine, organophosphorus pesticides and nerve agents. 
This thesis is to develop a recombinant human BChE bioprocess in a laboratory 
scale. The first aim of this project is to develop an efficient rhBChE expression system in 
CHO cells. On the exploration of different performance of various promoters, effect of 
codon optimization and effect of C-terminal his tag together, the vector pEF6/EF/O-
BCHE-HIS containing the codon-optimized BCHE gene under the control of the EF 
promoter (elongation factor 1a) and a C-terminal his-tag was selected as an efficient 
rhBChE expression construct. 
The second aim of this project involves the enhancement of  rhBChE self-assembly 
into tetramers by genetic approach. In the preliminary study, three proline-rich sequences 
with various proline residues (P8, P14 and P24) were introduced in rhBChE stably 
expressing cell line and P24 organized approximately 60% of rhBChE into tetramers, 
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which was chosen as the most efficient rhBChE tetramer organizer compared to other two 
counterparts. Furthermore, pcDNA3.1 P24-IRES-GFP vector was constructed and 
fluorescence activated cell sorting was applied to further increase the expression of P24 in 
rhBChE cell line. After sorting, the P24-rhBChE stable pool was able to stably express 
rhBChE with a high content of tetrameric isomer and improved enzymatic activity. 
We also studied the Ni-NTA purification efficiency to purify rhBChE, which 
showed 20% recovery rate and did not change the distribution of rhBChE-his isomers in 
CHO cells. Thus, Ni-NTA purification with its affinity to his-tagged protein can be used 










CHAPTER 6: FUTURE WORK 
Two critical factors that determine the BChE enzymatic activity, stability and half-
life are tetrameric content and glycosylation. Native BChE in human plasma consists of 
95% tetramer [32]. Since we have found an efficient approach to solve the low-tetramer 
issue in recombinant human BChE, the next step would be to optimize the glycosylation 
pattern of rhBChE in CHO cells. I have outlined the main plans for the future study as 
below. 
6.1  FURTHER ENHANCE RHUBCHE TETRAMERIZATION BY EUKARYOTIC 
TRANSLATION INITIATION FACTOR 5A-1 
 
Eukaryotic initiation factor 5A (eIF5A) is a small, acidic protein essential for cell 
proliferation, which represents the only known eukaryotic protein activated by 
posttranslational hypusination [41]. eIF5A is highly conserved throughout eukaryotes. 
Sequence conservation is especially high around the hypusine residue, underlining the 
meaning of this unusual protein modification throughout eukaryotic evolution. Although 
eIF5A is intimately involved in eukaryotic cell proliferation, the true physiological 
function of this essential factor has yet to be elucidated. Park et al. [42]mentioned that 
eIF5A may be a bimodular protein interacting with both RNA and proteins, and is 
presumed to have an important role in the translation machinery.  
Thus the next step we will transiently transfect elf5A gene in rhuBChE-P24 sorted 
cells and examine the content of rhuBChE tetramerization using native electrophoresis.  
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6.2 TEST THE STABILITY OF PURIFIED RHUBCHE TETRAMERS CHAPERONED 
WITH P24 
 
Protein stability is important for its storage and transportation. And the repeated 
freeze-thaw cycles will decrease protein stability. Thus we want to test the stability of 
purified rhuBChE tetramer chaperoned with P24 using repeated slow freeze and fast thaw 
cycles [43]. Also with the assistance of native electrophroresis, we will determine the 
degradation of rhuBChE tetramer due to the numbers of freeze and thaw cycles.  
6.3 GLYCAN ANALYSIS 
 After protein purification, the N-linked oligosaccharides will be cleaved from 
rhuBChE and treated with various enzymes to determine the Sialic Acid/Galactose ratio. 
Then we will examine the alpha (2-3)-sialic acid content on rhuBChE glycans of the 
engineered cell lines. We will treat purified recombinant proteins with an alpha (2-3)-
specific neuraminidase to remove alpha (2-3)-linked sialic acids. The resulting glycans will 
be removed from the peptides using glycosidases and analyzed using multi-dimensional 
mass spectrometry (MS).  
In the future, we hope to be able to perform in vitro activity and OP inhibition 
assays with our recombinant huBChE to see the effects of the genetically-engineered CHO 
cell lines. Ultimately, we want to examine the in vivo circulatory lifetime of rhuBChE, 
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